This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Platelet-activating factor acetylhydrolase 1b catalytic subunit 3 (PAFAH1B3)	<i>In vitro</i> and mouse studies suggest inhibiting PAFAH1B3 could help treat breast cancer. In culture and in mouse xenograft models with a highly aggressive patient-derived breast cancer cell line, siRNA or shRNA against <i>PAFAH1B3</i> decreased proliferation, tumor cell survival and migration <i>in vitro</i> and tumor growth <i>in vivo</i> compared with control RNA. In a cultured human breast cancer cell line, knockdown of <i>PAFAH1B3</i> increased levels of multiple lipids with tumor-suppressive properties compared with no alteration. Next steps include investigating <i>PAFAH1B3</i> loss in other cancer types and developing a PAFAH1B3-specific inhibitor.	Patent status undisclosed; unavailable for licensing	Mulvihill, M.M. <i>et al. Chem. Biol.</i> ; published online June 19, 2014; doi:10.1016/j.chembiol.2014.05.008 Contact: Daniel K. Nomura, University of California, Berkeley, Calif. e-mail: dnomura@berkeley.edu
<i>SciBX</i> 7(30); doi:10.1038/scibx.2014.887 Published online Aug. 7, 2014				